HOME

GENERIC DRUGS

MANUFACTURING

DISTRIBUTION

PRODUCTS

CONTACT US

ONCOLOGY

The most common type of breast cancer is ductal carcinoma, which begins in the cells of the ducts. Cancer that begins in the lobes or lobules is called lobular carcinoma and is more often found in both breasts than are other types of breast cancer. Inflammatory breast cancer is an uncommon type of malignancy, which causes the breast to become warm, red and swollen. Estrogen promotes growth of the breast cancer cells, and therefore treatment often involves the use of estrogen inhibitors.

Tamoxifen (brand name NOVALDEX^®) works against the effects of estrogen on cancer cells and has been used for more than 20 years to treat or prevent breast cancer. As a treatment of breast cancer, the drug slows or stops the growth of cancer cells that are present in the body. As adjuvant therapy, Tamoxifen helps prevent the original breast cancer from returning and also helps prevent the development of new cancers in the other breast. It is the hormonal treatment of choice for pre-menopausal women, and may also be used to treat other conditions as determined by the attending physician.

The National Cancer Institute (NCI) in the United States, funded a large research study to determine the usefulness of Tamoxifen in preventing breast cancer in women who have an increased risk of developing the disease. This study, known as the Breast Cancer Prevention Trial (BCPT), was conducted by the National Surgical Adjuvant Breast and Bowel Project (NSABP), a component of the NCI’s Clinical Trials Cooperative Group Program. The study found a 49 percent reduction in diagnoses of invasive breast cancer among women who took Tamoxifen, and 50 percent fewer diagnoses of noninvasive breast tumors, such as ductal or lobular carcinoma in situ.

Tamoxifen
 

TABLET - ORAL
 

Click here to view Tamoxifen Detailed Information